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Poster Session II S303population ranging up to 80% at an effector to target ratio of 40:1.
The LSC population however was found to be uniformly less sensi-
tive to NK cells than the non-LSC blast population, exhibiting apo-
ptosis that was 45-85% of the more mature population (p5 0.0002
at 10:1 effector-to-target ratio; p5 0.017 at 40:1 effector-to-target
ratio).
Conclusions: Immunophenotypically-defined AML stem cells show
a reduced sensitivity to killing by allogeneic NK cells, a result that
may be related to lower levels of expression of the activating ligands
MICA/B and CD48. These results may have implications for the
utility of natural killer cells in eradicating AML.394
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Chronic graft versus host disease (CGHD) remains a major non-
relapse source of morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (HSCT), but little is known
of its pathogenesis. As part of an ongoingNCI CGVHDnatural his-
tory protocol (04-C-0281), paired affected and unaffected skin biop-
sies were collected from patients with cutaneous CGVHD. Using
multi-parameter fluorescent immunohistochemistry, we assessed
the dense subepidermal infiltrate of mononuclear cells in skin biop-
sies with lichenoid histological findings in 9 patients. The primary T
cell population in affected skin biopsies consisted of Th1/Tc1 cells
expressing the transcription factor T-Bet. CD8 +T cells predomi-
nated in tissue from patients fewer than 9 months after HSCT, but
were less than CD8-CD3+ cells in biopsies taken from patients
more than one year after HSCT. Both CD68+ myeloid cells in the
dermal infiltrate and epidermal keratinocytes expressed elevated
levels of Interferon (IFN) inducible factors, including MxA and the
chemokineMIG (CXCL9). Concomitantly, most T cells in the infil-
trate expressed the T-Bet induced receptor CXCR3 that bindsMIG.
These findings are consistent with a pathogenic process in which
IFN produced by keratinocytes and infiltrating myeloid elements
could support the recruitment of CXCR3+ effector cells into the
skin. Elevated levels of IFN-inducible factors are also evident sys-
temically. When cells from normal donors were cultured with as
little as 2 pg/ml of Type I IFN,mRNA expression of the IFN-induc-
ible genes BAFF, MxA and IFI44 increased by 2 to 4 logs. Plasma
levels of the IFN-inducible factors MIG and BAFF were elevated
in these patients (MIG median 1813 pg/ml; range 125-7440; BAFF
median 4512; range 1453-14907 pg/ml) compared with normal
donors. These data, and comparable observations we have made in
oral CGVHD (Imanguli, Blood, 2009), support the hypothesis that
IFN-mediated processes contribute to epithelial tissue damage in
CGVHD.395
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We have previously demonstrated that activation of STAT1 and
STAT3 in GVHD target tissues and secondary lymphoid organs be-
long to the earliest events during induction of GVHD. Using
STAT1-gene-deficient (STAT1KO) mice we tested the role of do-
nor STAT1 during GVHD induction in fully MHC-mismatched
(129Sv[H2b] to BALB/c [H2d]) and MHC-matched minor histo-
compatibility antigen (mHA)-mismatched BMT (129Sv[CD45.2,
H2b] to B6 [H2b] or B6.SJL [CD45.1, H2b] following lethal irradi-
ation. Using STAT1KO whole splenocytes we were able to showthat lack of STAT1 significantly inhibited development of GVHD
in both major and mHAmismatched recipients with significantly ex-
tended median survival times (MST), lower GVHD morbidity and
less inflammation in GVHD target tissue samples. Protection
against GVHD in recipients of STAT1KO splenocytes was associ-
ated with significant inhibition of T cell activation as determined
by changes in CD25, CD69 and CD62L expression on donor
CD4+ and CD8 + T cells on days +6 post-BMT. Lack of STAT1
in donor splenocytes resulted in a significantly attenuated and
skewed systemic inflammatory response on day +6 post-BMT as
demonstrated by significantly reduced IFN-g levels (p\0.05), but
significantly increased IL-4 (p5 0.003), IL-5 (p5 0.007) and IL-
17 (p5 0.03) levels. In vitro studies demonstrated that STAT1KO
CD8 +T cells produced much less IFN-g upon combined engage-
ment of TCR and costimulation, but that this decrease in IFN-g se-
cretion could be rescued if cells were simultaneously cultured under
Th1 conditions (i.e. in the presence of IL-12 and anti-IL4 antibody).
In contrast, lack of STAT1 completely inhibited the differentiation
of naive CD4 + T cells to IFN-g-producing cells upon TCR
commitment and this capacity was also severely impaired under
Th1 conditions. These findings were confirmed in vivo in the
MHC-mismatched GVHD setting as we were able to observe a sig-
nificantly reduced number of donor-derived CD4 + IFN-g-produc-
ing cells in recipients of STAT1 KO (p5 0.018) compared to
recipients of WT cells, while there was no difference with regard
to IFN-g expression in CD8 +T cells. Most importantly, we ob-
served a significant expansion of CD4 +CD25 + FOXP3 +Treg cells
in recipients of STAT1KO splenocytes in both major MHC-mis-
matched and MHC-matched mHA-mismatched setting. Currently,
studies are ongoing to assess the role of STAT1 in the generation
and function of Treg cells during GVHD.396
A LOWER FOXP3 + T-REG/CD4 + CELLS RATIO EARLY AFTER HSCT MAY
IDENTIFY PATIENTS AT RISK FOR ALLO-REACTIVE DISEASE
de Pagter, P.J.A.1, Lindemans, C.A.1, Reubsaet, L.L.3, Baarle, D.1,2,
Keukens, L.1, Nanlohy, N.1, Sanders, E.A.M.1, Prakken, B.3,
Kleer, I.M.3, Boelens, J.J.1 1Wilhelmina Children’s Hospital, University
Medical Center Utrecht, Utrecht, Netherlands; 2Wilhelmina Children’s
Hospital, University Medical Center Utrecht, Utrecht, Netherlands;
3Wilhelmina Children’s Hospital, University Medical Center Utrecht,
Utrecht, Netherlands
Regulatory CD4 + FOXP3 +T-cells (FOXP3 +Treg) are sug-
gested to play a role in control of allo-reactive disease after haema-
topoietic stem cell transplantation (HSCT). We analyzed
FOXP3 +Treg in relation to allo-reactive disease after cord blood
(u-CB), matched unrelated donor (MUD) or identical sibling (id-
Sib) HSCT.
In this prospective cohort study, absolute CD4 +T-cell numbers
and the ratio of FOXP3 +Treg of total CD4 + T-cells were analyzed
every other week by direct whole blood Fluorescence-activated cell
sorting analysis. Early allo-reactive disease (\100days) was defined
as acute Graft-versus-Host-Disease and/or idiopathic pulmonary
syndrome after HSCT.
A total of 32 pediatric patients were included. Following myeloa-
blative conditioning, 7 (22%) patients received aMUD, 13 (41%) id-
Sib and 12 (38%) u-CB HSCT. These three patient groups showed
significant differences in the FOXP3 +Treg reconstitution pattern.
The FOXP3 +Treg/CD4+ ratio was higher in the first 6 weeks after
id-Sib-HSCT compared to u-CB or MUD HSCT (p5 0.018). In
u-CB recipients, the FOXP3 +Treg reconstitution was relatively
slow. 12 of the 32 patients developed allo-reactive disease (8 aGvHD
and 4 IPS). Overall, FOXP3 +Treg/CD4+ ratios were lower in
patients prior to the developed allo-reactive disease compared to
patients without allo-reactive disease (p5 0.010).
Development of allo-reactive disease is preceded by a low ratio of
FOXp3 + Treg/CD4 + early after HSCT. The FOXP3 +Treg/CD4
ratio early (6 weeks) after HSCTmight be used to identify patients at
risk for allo-reactive disease and to guide immunosuppressive or im-
muno-therapy. Influencing the ratio of FOXP3 +Treg/CD4+ in vivo
may influence the incidence of allo-reactive disease and may make
HSCT safer.
